NEXIEN BIOPHARMA, INC.
CIK 0001625288
Revenue (TTM)
$0
Q3 May 2025
Net Income (TTM)
−$154.73K
+33.9% YoY
Q3 May 2025
EPS Diluted (TTM)
$0.00
+100.0% YoY
Q3 May 2025
Gross Margin
—
Q3 May 2025
Operating Margin
—
Q3 May 2025
Net Margin
—
Q3 May 2025
Free Cash Flow (TTM)
—
Q3 May 2025
Cash
$8.29K
Q3 May 2025
Total Debt
—
Q3 May 2025
Shares Outstanding
70.77M sh
Q3 May 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.